Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$285.41
+3.5%
$290.57
$253.30
$339.17
$148.50B0.491.99 million shs8.73 million shs
Biogen Inc. stock logo
BIIB
Biogen
$142.50
-0.9%
$135.01
$110.04
$200.37
$21.08B0.111.49 million shs3.75 million shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$114.09
+0.4%
$114.10
$81.83
$121.83
$140.98B0.365.84 million shs12.58 million shs
Illumina, Inc. stock logo
ILMN
Illumina
$102.75
-0.3%
$99.78
$68.70
$156.66
$15.84B1.431.31 million shs3.62 million shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
+0.41%-2.44%-6.67%-4.67%-17.15%
Biogen Inc. stock logo
BIIB
Biogen
-0.73%-3.38%+3.56%+13.20%-27.22%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
+1.21%-3.60%-3.70%+4.72%+35.44%
Illumina, Inc. stock logo
ILMN
Illumina
+2.14%+3.75%+1.41%+13.86%-21.33%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$285.41
+3.5%
$290.57
$253.30
$339.17
$148.50B0.491.99 million shs8.73 million shs
Biogen Inc. stock logo
BIIB
Biogen
$142.50
-0.9%
$135.01
$110.04
$200.37
$21.08B0.111.49 million shs3.75 million shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$114.09
+0.4%
$114.10
$81.83
$121.83
$140.98B0.365.84 million shs12.58 million shs
Illumina, Inc. stock logo
ILMN
Illumina
$102.75
-0.3%
$99.78
$68.70
$156.66
$15.84B1.431.31 million shs3.62 million shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
+0.41%-2.44%-6.67%-4.67%-17.15%
Biogen Inc. stock logo
BIIB
Biogen
-0.73%-3.38%+3.56%+13.20%-27.22%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
+1.21%-3.60%-3.70%+4.72%+35.44%
Illumina, Inc. stock logo
ILMN
Illumina
+2.14%+3.75%+1.41%+13.86%-21.33%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.24
Hold$304.436.66% Upside
Biogen Inc. stock logo
BIIB
Biogen
2.32
Hold$181.6527.48% Upside
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.89
Moderate Buy$117.172.70% Upside
Illumina, Inc. stock logo
ILMN
Illumina
2.21
Hold$123.0619.76% Upside

Current Analyst Ratings Breakdown

Latest AMGN, BIIB, GILD, and ILMN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/16/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$135.00 ➝ $145.00
9/12/2025
Biogen Inc. stock logo
BIIB
Biogen
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$115.00 ➝ $118.00
9/12/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$136.00 ➝ $143.00
9/5/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Dbs Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeModerate Buy
9/4/2025
Biogen Inc. stock logo
BIIB
Biogen
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
9/3/2025
Amgen Inc. stock logo
AMGN
Amgen
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Perform
9/2/2025
Illumina, Inc. stock logo
ILMN
Illumina
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$124.00
8/25/2025
Amgen Inc. stock logo
AMGN
Amgen
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$328.00 ➝ $342.00
8/19/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Daiwa America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldStrong-Buy
8/19/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Daiwa Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutralOutperform$128.00
8/14/2025
Biogen Inc. stock logo
BIIB
Biogen
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$115.00 ➝ $118.00
(Data available from 9/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$33.42B4.60$31.43 per share9.08$10.93 per share26.11
Biogen Inc. stock logo
BIIB
Biogen
$9.68B2.16$22.91 per share6.22$114.71 per share1.24
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$28.75B4.92$6.90 per share16.54$15.44 per share7.39
Illumina, Inc. stock logo
ILMN
Illumina
$4.37B3.61$4.68 per share21.96$14.96 per share6.87
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$4.09B$12.2323.3413.342.4018.96%174.71%13.12%10/29/2025 (Estimated)
Biogen Inc. stock logo
BIIB
Biogen
$1.63B$10.4613.628.631.1315.31%13.85%8.32%10/29/2025 (Estimated)
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$480M$5.0222.7314.070.7721.86%50.99%17.24%11/5/2025 (Estimated)
Illumina, Inc. stock logo
ILMN
Illumina
-$1.22B$7.9013.0119.912.3229.36%28.93%10.74%11/3/2025 (Estimated)

Latest AMGN, BIIB, GILD, and ILMN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$1.96$2.01+$0.05$1.55$6.95 billion$7.08 billion
8/5/2025Q2 2025
Amgen Inc. stock logo
AMGN
Amgen
$5.28$6.02+$0.74$2.65$8.86 billion$9.18 billion
7/31/2025Q2 2025
Biogen Inc. stock logo
BIIB
Biogen
$3.93$5.47+$1.54$4.33$2.32 billion$2.65 billion
7/31/2025Q2 2025
Illumina, Inc. stock logo
ILMN
Illumina
$1.02$1.19+$0.17$1.50$1.12 billion$1.06 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$9.523.34%N/A77.84%14 Years
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.162.77%N/A62.95%10 Years
Illumina, Inc. stock logo
ILMN
Illumina
N/AN/AN/AN/AN/A

Latest AMGN, BIIB, GILD, and ILMN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/29/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
quarterly$0.792.81%9/15/20259/15/20259/29/2025
8/1/2025
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.383.21%8/22/20258/22/20259/12/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
7.24
1.31
0.98
Biogen Inc. stock logo
BIIB
Biogen
0.36
2.50
1.79
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1.13
1.32
1.15
Illumina, Inc. stock logo
ILMN
Illumina
0.66
1.81
1.41

Institutional Ownership

CompanyInstitutional Ownership
Amgen Inc. stock logo
AMGN
Amgen
76.50%
Biogen Inc. stock logo
BIIB
Biogen
87.93%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
83.67%
Illumina, Inc. stock logo
ILMN
Illumina
89.42%

Insider Ownership

CompanyInsider Ownership
Amgen Inc. stock logo
AMGN
Amgen
0.76%
Biogen Inc. stock logo
BIIB
Biogen
0.18%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.27%
Illumina, Inc. stock logo
ILMN
Illumina
2.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
28,000538.36 million534.27 millionOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,605146.62 million146.35 millionOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
17,6001.24 billion1.24 billionOptionable
Illumina, Inc. stock logo
ILMN
Illumina
9,030153.70 million149.70 millionOptionable

Recent News About These Companies

Illumina, Inc. $ILMN Shares Purchased by Swedbank AB
Swedbank AB Cuts Position in Illumina, Inc. $ILMN
Why Illumina (ILMN) Stock Is Falling Today

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Amgen stock logo

Amgen NASDAQ:AMGN

$285.41 +9.58 (+3.47%)
Closing price 04:00 PM Eastern
Extended Trading
$284.88 -0.54 (-0.19%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Biogen stock logo

Biogen NASDAQ:BIIB

$142.50 -1.31 (-0.91%)
Closing price 04:00 PM Eastern
Extended Trading
$142.38 -0.12 (-0.09%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Gilead Sciences stock logo

Gilead Sciences NASDAQ:GILD

$114.09 +0.47 (+0.41%)
Closing price 04:00 PM Eastern
Extended Trading
$113.75 -0.34 (-0.30%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Illumina stock logo

Illumina NASDAQ:ILMN

$102.75 -0.28 (-0.27%)
Closing price 04:00 PM Eastern
Extended Trading
$102.99 +0.24 (+0.23%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.